CS1
Pulmonary Arterial Hypertension (PAH)
Phase IIActive - Phase IIa completed; Phase IIb in preparation
Key Facts
Indication
Pulmonary Arterial Hypertension (PAH)
Phase
Phase II
Status
Active - Phase IIa completed; Phase IIb in preparation
Company
About Cereno Scientific
Cereno Scientific is a Swedish clinical-stage biotech company developing first-in-class epigenetic therapies targeting the root causes of rare cardiovascular and pulmonary diseases. The company's lead program, CS1, has demonstrated disease-modifying potential in a Phase IIa trial for PAH and holds FDA Fast Track designation, while its broader HDACi portfolio and preclinical prostacyclin receptor agonist CS585 address significant unmet medical needs. With a strengthened focus on rare diseases, Cereno aims to deliver high treatment value through a business model characterized by relatively shorter development timelines and reduced capital requirements.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension (PAH) Drugs
| Drug | Company | Phase |
|---|---|---|
| ANPA-0073 | Structure Therapeutics | Preclinical |
| YUTREPIA™ (treprostinil) inhalation powder | Liquidia Corporation | Approved (Tentative) |
| LIQ861 (treprostinil) inhalation powder | Liquidia Corporation | Phase 3 |
| KER-012 | Keros Therapeutics | Phase 2 |
| Seralutinib | Gossamer Bio | Phase 3 |
| NTP42 | ATXA Therapeutics | Phase 1 |